406 related articles for article (PubMed ID: 16842188)
1. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
Oliveira JS; de Sousa EH; de Souza ON; Moreira IS; Santos DS; Basso LA
Curr Pharm Des; 2006; 12(19):2409-24. PubMed ID: 16842188
[TBL] [Abstract][Full Text] [Related]
2. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
[TBL] [Abstract][Full Text] [Related]
3. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
Inturi B; Pujar GV; Purohit MN
Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
[TBL] [Abstract][Full Text] [Related]
5. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
Rawat R; Whitty A; Tonge PJ
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13881-6. PubMed ID: 14623976
[TBL] [Abstract][Full Text] [Related]
6. An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
Oliveira JS; Sousa EH; Basso LA; Palaci M; Dietze R; Santos DS; Moreira IS
Chem Commun (Camb); 2004 Feb; (3):312-3. PubMed ID: 14740053
[TBL] [Abstract][Full Text] [Related]
7. Conformational changes in 2-trans-enoyl-ACP (CoA) reductase (InhA) from M. tuberculosis induced by an inorganic complex: a molecular dynamics simulation study.
da Costa AL; Pauli I; Dorn M; Schroeder EK; Zhan CG; de Souza ON
J Mol Model; 2012 May; 18(5):1779-90. PubMed ID: 21833828
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates.
Basso LA; Zheng R; Musser JM; Jacobs WR; Blanchard JS
J Infect Dis; 1998 Sep; 178(3):769-75. PubMed ID: 9728546
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.
Parikh SL; Xiao G; Tonge PJ
Biochemistry; 2000 Jul; 39(26):7645-50. PubMed ID: 10869170
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.
Lu XY; You QD; Chen YD
Mini Rev Med Chem; 2010 Mar; 10(3):181-92. PubMed ID: 20408801
[TBL] [Abstract][Full Text] [Related]
11. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
[TBL] [Abstract][Full Text] [Related]
12. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
[TBL] [Abstract][Full Text] [Related]
13. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities.
Vilchèze C; Jacobs WR
Microbiol Spectr; 2014 Aug; 2(4):MGM2-0014-2013. PubMed ID: 26104204
[TBL] [Abstract][Full Text] [Related]
14. Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.
Delaine T; Bernardes-Génisson V; Quémard A; Constant P; Meunier B; Bernadou J
Eur J Med Chem; 2010 Oct; 45(10):4554-61. PubMed ID: 20696503
[TBL] [Abstract][Full Text] [Related]
15. Enoyl reductases as targets for the development of anti-tubercular and anti-malarial agents.
Oliveira JS; Vasconcelos IB; Moreira IS; Santos DS; Basso LA
Curr Drug Targets; 2007 Mar; 8(3):399-411. PubMed ID: 17348833
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
Subba Rao G; Vijayakrishnan R; Kumar M
Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
[TBL] [Abstract][Full Text] [Related]
17. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
[TBL] [Abstract][Full Text] [Related]
18. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
[TBL] [Abstract][Full Text] [Related]
19. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
